Selling an ESOP-Owned Company: Trustee Duties, 1042 Rollovers & Repurchase Obligations

Selling an ESOP-owned company is fundamentally different from selling a privately held business. When an Employee Stock Ownership Plan owns part or all of the company’s stock, the ESOP trustee — not the founder, not the board, not the management team — has the legal authority to accept or reject offers. The trustee is bound by ERISA fiduciary duty to act in the exclusive interest of plan participants. Founders who don’t understand this often get blindsided when their preferred buyer is rejected by the trustee.

The trustee’s job is to get fair value for participants. Fair value is established by an independent appraiser through a fairness opinion. If a buyer offers below fair value, the trustee is legally obligated to reject the offer — even if the founder, the board, and the management team all support it. ERISA imposes personal liability on trustees who breach this duty, which is why trustees are conservative and process-driven.

The Section 1042 rollover creates a hidden constraint for many ESOP company sellers. If the original founder sold stock to the ESOP and elected Section 1042 treatment to defer capital gains, that deferral was contingent on holding qualified replacement property (QRP) — typically domestic operating company stocks or bonds. Selling the QRP triggers the deferred gain. Many founders forgot this constraint exists until they prepare for a second exit and discover it has tax consequences.

Repurchase obligations are the silent line item in every ESOP sale. ESOP-owned companies are required to buy back vested shares from employees who leave, retire, or become disabled. The cumulative liability for future repurchases is real, often substantial, and almost always under-funded. Buyers will model the repurchase obligation and deduct it from purchase price. Sellers who haven’t commissioned a recent repurchase study walk into negotiations blind.

“In a normal sale, the seller decides. In an ESOP sale, the trustee decides — and the trustee’s only client is the plan participant. The founder’s preferences are not binding.”

Key Takeaways

• The ESOP trustee — not the founder — has legal authority to accept or reject offers under ERISA. Fiduciary duty runs to plan participants, not to selling shareholders.
• A fairness opinion from an independent appraiser is mandatory. The trustee cannot accept an offer below fair market value. The valuation firm is the gatekeeper.
• Section 1042 rollover lets selling shareholders defer capital gains by reinvesting proceeds in qualified replacement property (QRP). The deferral lasts until QRP is sold.
• Repurchase obligations — the requirement to buy back vested shares from departing employees — create a balance sheet liability that buyers will deduct from price.
• ESOP-friendly deal structures include sale to strategics, PE recapitalizations with management rollover, sale to another ESOP, and leveraged recaps that pay out participants.
• Process matters. Trustees demand a competitive auction with multiple bidders to demonstrate they pursued best value for participants. Single-bidder negotiations often fail trustee scrutiny.

What makes an ESOP-owned company sale different

The trustee has decision-making authority, not the founder. In a non-ESOP company, the selling shareholder accepts or rejects offers. In an ESOP-owned company, the ESOP trustee accepts or rejects on behalf of plan participants. The trustee’s legal duty under ERISA is to act in the exclusive interest of participants — not the founder, not management, not the board. This single fact reshapes the entire sale process.

Fair value is the binding standard, not negotiated price. The trustee cannot accept an offer below fair market value as determined by an independent appraiser. If the highest bid is $50M and the appraiser values the company at $55M, the trustee must reject the bid — or at minimum require a documented justification (synergies, strategic premium, etc.) that supports the gap. Fair value is set by the valuation firm, not by market clearing.

The fairness opinion is the trustee’s legal protection. Trustees retain independent appraisers to issue fairness opinions stating that the transaction price is ‘fair, from a financial point of view, to plan participants.’ This document is the trustee’s primary defense against participant lawsuits. Without it, the trustee is personally exposed under ERISA. With it, the trustee has a documented, professional basis for the decision.

Process matters more than outcome. ERISA imposes a duty of process — trustees must demonstrate they ran a sound process, not just that they got a good price. A competitive auction with multiple bidders is the standard process. Single-bidder negotiations create vulnerability: even at a high price, the trustee can be challenged for not testing the market. Most ESOP sales run a controlled auction managed by an investment banker.

ESOP ownership structures and how each affects a sale

100% ESOP-owned S-corporations are the most common structure. These companies pay no federal income tax (the ESOP is a tax-exempt trust, and S-corps pass income through to shareholders). The founder typically sold their stock to the ESOP years earlier and the ESOP now owns 100% of the company. In a sale, all proceeds flow to the ESOP and are eventually distributed to participants over time.

Partial ESOP ownership creates more complex sales. Some companies are 30%, 49%, or 70% ESOP-owned with the rest held by the founder, family, or outside investors. In a sale, the ESOP’s portion is governed by trustee fiduciary duty; the rest can be sold normally. Buyers must negotiate with both the trustee (for the ESOP shares) and the other shareholders (for their shares) — sometimes at different effective prices, which raises additional ERISA concerns.

Leveraged ESOPs add a third layer of complexity. Many ESOPs were established with internal loans — the company borrowed money to buy founder stock and lent it to the ESOP. If that loan is still outstanding at the time of sale, it must be repaid as part of the transaction. The proceeds flow first to retire the ESOP debt, then to the participants’ accounts. Trustees must verify the loan repayment doesn’t favor the company at participant expense.

Synthetic equity and management options coexist with ESOP ownership. Many ESOP-owned companies grant management synthetic equity (phantom stock, stock appreciation rights) or stock options outside the ESOP. In a sale, these instruments must be valued, exercised or cashed out, and reconciled with the ESOP’s rights. Management often holds a meaningful percentage through these synthetic instruments, which can create alignment or conflict with the ESOP’s interests.

The trustee’s fiduciary duty under ERISA

ERISA Section 404 imposes the duty of prudence and exclusive purpose. The trustee must act with the care, skill, prudence, and diligence of a prudent person familiar with such matters — and solely in the interest of plan participants and beneficiaries. This is one of the most demanding fiduciary standards in U.S. law. Personal liability attaches if the trustee breaches this duty.

The trustee cannot favor the founder, the board, or management. If the founder wants to sell to a buyer who will preserve company culture, but the appraiser concludes a different buyer offers materially higher value, the trustee must accept the higher-value bid. If management prefers Buyer A because they get rollover equity, but Buyer B offers more for the ESOP shares, the trustee must accept Buyer B (or document why Buyer A is actually better for participants on a risk-adjusted basis).

Independent appraisers and independent trustees are common. Many ESOP-owned companies appoint a special independent transaction trustee for the sale process. This is a third-party fiduciary (typically a trust company or specialized firm) brought in solely to handle the sale. The independent trustee has no other relationship with the company, eliminating conflict of interest concerns. This is best practice for any meaningful sale process.

The DOL pays attention to ESOP transactions. The U.S. Department of Labor has jurisdiction over ERISA fiduciary breaches and has historically been active in ESOP matters. Inadequate fairness opinions, sweetheart deals to founders, and failure to run a competitive process can all draw DOL scrutiny. Trustees structure transactions defensively to anticipate DOL review.

The fairness opinion and independent appraisal

An independent appraisal firm values the company. The trustee retains an ERISA-experienced valuation firm to determine fair market value. The appraisal uses standard methodologies: discounted cash flow, public company comparables, precedent M&A transactions, and asset-based approaches. The output is a defensible range of values that the trustee uses as the floor for accepting offers.

The fairness opinion is issued at closing. Once a deal is negotiated, the appraiser issues a written fairness opinion stating whether the transaction is fair, from a financial point of view, to plan participants. The opinion considers the negotiated price, the form of consideration (cash, stock, seller note), the proposed deal terms, and the timing. A fairness opinion is not an audit of value; it’s a professional judgment that the deal is reasonable.

Buyers must accommodate the fairness opinion process. The appraiser will demand access to financial records, management forecasts, and customer/industry data. Buyers must allow the appraiser to validate the company’s information without compromising the buyer’s own diligence. This adds 30-60 days to typical deal timelines and can create awkward moments when the appraiser’s conclusion differs from the buyer’s.

If the fairness opinion comes in below the buyer’s offer, the trustee accepts. If the fairness opinion comes in above the buyer’s offer, the trustee may reject the deal — or push the buyer to increase price. The fairness opinion effectively becomes the trustee’s minimum price. Buyers should expect this dynamic and price their offers accordingly.

Section 1042 rollover: the founder’s tax constraint

Section 1042 lets a selling shareholder defer capital gains on a sale to an ESOP. If the founder sold stock to the ESOP, the company was a C-corporation at the time of sale, the ESOP owned at least 30% of the stock immediately after the transaction, and the founder reinvested the proceeds in qualified replacement property (QRP) within 12 months, then the capital gain is deferred — potentially indefinitely if the QRP is never sold.

Qualified replacement property is the catch. QRP must be securities of domestic operating companies — not REITs, mutual funds, or government bonds. Common QRPs are stocks of operating companies and floating rate notes. The QRP must be held until death (when basis steps up and the deferred gain is eliminated) or sold (which triggers the deferred gain plus any new appreciation).

Selling the QRP triggers the deferred gain. If the founder sold stock to the ESOP in 2010 with $20M of deferred gain, and now in 2026 needs liquidity and sells the QRP, the entire $20M of deferred gain becomes taxable in 2026 at long-term capital gains rates (plus net investment income tax). This is why founders often hold QRP indefinitely and use margin loans against it for liquidity rather than selling.

Planning around 1042 requires advance work. Founders considering a sale should consult tax advisors well before any transaction. Strategies include: (1) gifting QRP to children or charitable trusts to reset basis; (2) using the QRP as collateral for borrowing rather than selling; (3) timing the sale to occur after death to use the basis step-up; (4) electing not to use 1042 in the original ESOP sale if the founder anticipated a near-term liquidity event.

Repurchase obligations: the silent balance sheet item

ESOP-owned companies must buy back vested shares from departing employees. When an employee retires, terminates, becomes disabled, or dies, the company is required to repurchase their vested ESOP shares at fair market value. This obligation grows over time as participants accumulate vested shares and approach retirement. Repurchase obligations are a real liability, even though they don’t appear on standard balance sheets.

Repurchase studies project the future obligation. Specialized actuarial firms perform repurchase studies that project the company’s repurchase obligation over 5, 10, and 20 years. The study models employee demographics, vesting schedules, expected stock value, and turnover. Output is a year-by-year repurchase obligation forecast. Most ESOP companies commission a repurchase study every 2-3 years.

Buyers deduct repurchase obligations from purchase price. Sophisticated buyers model the repurchase obligation as an off-balance-sheet liability and reduce their bid accordingly. A $100M ESOP company with $15M of present-value repurchase obligation effectively has $85M of equity value to the buyer. Sellers who haven’t modeled this concession in advance get unpleasantly surprised at LOI.

Some buyers actively prefer ESOP-owned targets despite the obligation. Strategic buyers and PE firms with patient capital sometimes view repurchase obligations as manageable. The cash outflow is predictable and spread over years. The labor stability and low employee turnover often associated with ESOP companies can offset the cost. Buyers who don’t understand ESOP repurchase mechanics tend to overprice or underprice; those who do understand can acquire ESOP companies at fair prices.

ESOP-friendly deal structures

Sale to a strategic buyer is the most common structure. A strategic buyer (competitor, complementary business, or new market entrant) acquires 100% of the ESOP’s shares for cash. The ESOP is terminated, participants’ accounts are distributed (cash or rollover to IRAs), and the company becomes part of the strategic acquirer. This is clean, taxable to participants on distribution, and offers no continuity for the ESOP structure.

Sale to a PE firm with management rollover. A PE firm acquires the company. The ESOP is cashed out at fair market value (with fairness opinion). Management may roll over a portion of their equity (synthetic or actual) into the new PE-controlled entity. Some structures preserve a small ESOP component post-close, but this is rare. Most sales fully terminate the ESOP.

Sale to another ESOP — sometimes possible. An ESOP-owned company can sell to another ESOP or to a buyer who will establish a new ESOP. This preserves the broad employee ownership structure but is operationally complex. The new buyer must have the financial capacity to leverage the ESOP and structure the transaction in a way the trustee finds fair. ESOP-to-ESOP sales are uncommon but increasing as ESOP-friendly investor groups mature.

Leveraged recapitalization — an alternative to sale. Instead of selling to an outside buyer, the ESOP company can borrow money and use the proceeds to distribute cash to participants. This is not a sale per se — the company remains ESOP-owned — but it provides liquidity for participants. Leveraged recaps are favored by trustees when they want to provide participant liquidity without giving up the ESOP structure.

Process: how an ESOP-owned company sale actually runs

Step 1: Engage advisors and an independent transaction trustee. The board engages an investment banker (typically one with ESOP transaction experience), a law firm with ERISA expertise, and a special independent transaction trustee. The independent trustee replaces or supplements the regular plan trustee for the duration of the sale process. Total advisor cost: typically $1.5-3.5M for mid-market deals.

Step 2: Pre-sale repurchase study and updated valuation. Before going to market, commission an updated repurchase study and refresh the company’s annual ESOP valuation. These documents become baseline data for the sale process. Buyers will request both, and trustees will use them to evaluate offers.

Step 3: Run a controlled auction. The investment banker prepares marketing materials, identifies a curated buyer list, runs first-round bids, narrows to a shortlist for management presentations and detailed diligence, and runs a final round of negotiations. The auction process is essential to demonstrate trustee process. Single-bidder negotiations are disfavored unless documented as superior to a market test.

Step 4: Final negotiation and fairness opinion. Once a winning bidder is selected, terms are finalized. The independent appraiser issues the fairness opinion. The trustee approves the deal in writing. Closing typically follows 60-120 days later after final diligence, regulatory approvals (HSR if applicable), and ERISA-related notices. Total deal timeline from kickoff to close: 9-15 months for most mid-market ESOP transactions.

Conclusion

Selling an ESOP-owned company is not selling a private company — it’s a fiduciary process governed by ERISA. The trustee, not the founder, decides whether to accept an offer. The fairness opinion, not the negotiation, sets the floor. The repurchase obligation, not the audited balance sheet, determines effective price. And the Section 1042 rollover — if the founder elected it years earlier — quietly constrains how proceeds can be reinvested. Founders who treat an ESOP company sale like a normal sale get blindsided by trustee rejections, fairness opinion gaps, and tax surprises. Founders who understand the rules — and engage ESOP-experienced bankers, lawyers, and trustees early — close clean transactions at fair value. The structures exist (strategic sale, PE recapitalization, sale to another ESOP, leveraged recap), but each requires careful sequencing. Start with a repurchase study, an updated valuation, and an honest assessment of what your buyer universe will pay for an ESOP-owned target.

Frequently Asked Questions

Can a founder force the sale of an ESOP-owned company?

No. Once an ESOP owns the stock, the trustee — not the founder — decides whether to accept any offer. The trustee’s fiduciary duty is to plan participants under ERISA, not to the founder. A founder who wants to sell against the trustee’s judgment has limited recourse beyond replacing the trustee, which itself triggers fiduciary scrutiny.

Who pays for the fairness opinion in an ESOP sale?

The company pays. The independent appraiser is retained by the trustee but the cost is borne by the company itself (or by the ESOP, depending on structure). Typical fairness opinion cost: $150k-500k for mid-market deals, depending on company complexity and the appraiser’s reputation.

What is Section 1042 and how does it affect the sale?

Section 1042 is a tax provision that lets a founder defer capital gains when selling stock to an ESOP, provided the company was a C-corporation, the ESOP owned at least 30% post-sale, and the founder reinvested proceeds in qualified replacement property (QRP) within 12 months. If the founder elected 1042 years ago and is now selling the company, the deferred gain remains tied to the QRP — selling QRP triggers the deferred tax.

What is qualified replacement property (QRP)?

QRP is securities of domestic operating companies. Eligible: stocks and bonds of U.S. operating businesses. Not eligible: REITs, mutual funds, government bonds, or foreign securities. The 1042 election requires the founder to reinvest proceeds in QRP within 12 months of the ESOP sale and hold the QRP to maintain deferral.

What is a repurchase obligation?

ESOP-owned companies must buy back vested shares from employees who retire, terminate, become disabled, or die. The cumulative future obligation is real and grows over time as participants accumulate shares. Sophisticated buyers model the present value of the repurchase obligation and deduct it from purchase price. Most ESOP companies commission repurchase studies every 2-3 years.

Can an ESOP-owned company sell to a private equity firm?

Yes. PE firms regularly buy ESOP-owned companies. The ESOP is typically terminated at close (cashed out at fair market value with a fairness opinion), and management may roll equity into the new PE-controlled entity. The transaction is structurally similar to a normal PE acquisition but with the additional ERISA-required steps (fairness opinion, trustee approval, participant notice).

Why do trustees prefer competitive auctions?

ERISA imposes a duty of process. A competitive auction with multiple bidders is the strongest evidence that the trustee tested the market and obtained the best available price. Single-bidder negotiations — even at apparently fair prices — create vulnerability to participant claims that the trustee didn’t pursue best value. Most ESOP sales run a controlled auction managed by an investment banker.

Who is the independent transaction trustee and why hire one?

The independent transaction trustee is a third-party fiduciary (typically a trust company or specialized firm) appointed solely to oversee the sale process. The independent trustee has no other relationship with the company, eliminating conflict of interest concerns. Independent trustees are best practice for any meaningful ESOP sale and effectively required by the DOL in larger transactions.

Can an ESOP be transferred to a buyer post-close?

Sometimes. ESOP-to-ESOP sales are uncommon but possible. The buyer must establish (or already operate) an ESOP, and the structure must be financially viable. More commonly, the buyer acquires the company, terminates the ESOP, and provides participants with cash distributions or rollover IRAs. Pure ESOP continuity is rare in third-party sales.

What is a leveraged recapitalization in an ESOP context?

A leveraged recap is when the ESOP company borrows money and uses the proceeds to distribute cash to participants — without an outside buyer. The ESOP remains in place; participants get partial liquidity. This is favored by trustees who want to provide liquidity without losing the ESOP structure. It’s also a common alternative when the founder wants liquidity but no qualified buyer offers fair value.

How long does selling an ESOP-owned company take?

Typically 9-15 months from initial advisor engagement to close. The timeline is longer than a non-ESOP sale because of the additional ERISA-required steps: independent trustee engagement, repurchase study, valuation refresh, fairness opinion process, and participant notices. Smaller, well-prepared deals can close in 6-9 months; complex or partial-ESOP transactions can extend to 18+ months.

What happens to ESOP participants’ accounts at close?

Participants’ vested account balances are distributed in cash, rolled into IRAs, or distributed in installments per the ESOP plan terms. Distributions are taxable as ordinary income unless rolled into an IRA (which preserves tax deferral). Participants typically receive their distributions within 60-180 days of close depending on plan provisions. The exact timing and form is set by the plan document, not by the buyer.

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side deal origination firm headquartered in Sheridan, Wyoming. CT Acquisitions sources founder-led businesses for 75+ private equity firms, family offices, and search funds across the U.S. lower middle market ($1M–$25M EBITDA). Christoph writes about M&A from the perspective of someone on the phone with both sides of the deal table every week. Connect on LinkedIn · Get in touch